JP2005314312A - External preparation for skin which is suitable for preventing inflammation - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a technique for preventing inflammation from becoming severe and inhibiting runaway of inflammatory system. <P>SOLUTION: The external preparation for the skin contains (1) 0.00001-0.1 mass% sophoraflavanone G of formula 1 and (2) 0.01-1 mass% soy isoflavone and/or its glycoside. The sophoraflavanone G preferably derives from an alcohol extract of Sophora flavescens belonging to Leguminosae and is obtained by subjecting the alcohol extract to liquid-liquid extraction with ethyl acetate and water, concentrating an ethyl acetate phase and fractionating and purifying the ethyl acetate phase by column chromatography using silica gel as a carrier. The soy isoflavone preferably derives from a normal butyl alcohol extract of soybean and is obtained by adding water to the extract, subjecting it to liquid-liquid extraction, recovering a normal butyl alcohol phase and removing the solvent from it. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to an external preparation for skin, and more particularly to an external preparation for skin suitable for preventing inflammation.

  Inflammation in the skin occurs when the skin is damaged by excessive light or when the skin tissue is physically damaged or activated by inflammatory factors. It is said that it helps to prevent the invasion of pathogenic bacteria from the damaged site. However, such inflammatory factors, on the other hand, induce inflammation and can damage living tissues. In particular, when the skin is severely injured, the inflammatory factor runs away, and the biological damage is significantly more than the biological defense, and the mechanism related to inflammation becomes undesirable for the living body. It tends to end up. That is, there is a demand for the development of a means for preventing such a runaway inflammatory system in the living body.

  As a means for preventing inflammation from occurring, for example, a method of eliminating active oxygen using ascorbic acids (see, for example, Patent Document 1) A method of preventing inflammation using an amide of a branched fatty acid (for example, patents) (See Reference 2), and methods using active oxygen scavenging components such as mozuku (see, for example, Patent Document 3) are already known. However, these target inflammations are all caused by acne and the like. It is not an acute and severe inflammation caused by ultraviolet irradiation. These techniques cannot be applied to inflammation caused by ultraviolet irradiation.

  Soy isoflavones and / or glycosides thereof have serine protease inhibitory action (see, for example, Patent Document 4), lysate action (see, for example, Patent Document 5), collagen production promoting action (see, for example, Patent Document 6) ), Female hormone production promoting action (see Patent Document 7) and the like are known to exist, but the action on inflammation is not known.

  It is already known that Sophoraflavanone G is contained in Sophora flavescens. It is also known to have a tyrosinase inhibitory action. (For example, refer nonpatent literature 1) About sophoraflavanone G, it is also known that antibacterial action, alpha-MSH inhibitory action, etc. exist. (For example, see Patent Document 8, Patent Document 9, Patent Document 10, and Patent Document 11) However, the action for preventing inflammation is not known.

  A skin external preparation containing 1) Sophoraflavanone G in an amount of 0.00001 to 0.1% by mass, and 2) 0.01 to 1% by mass of soy isoflavone and / or its glycoside is completely known. Moreover, it is not known at all that the external preparation for skin having such a constitution has a preventive action against inflammation caused by ultraviolet irradiation.

JP-A-8-333260 JP 2001-39937 A JP 2001-335457 A JP 2003-95858 A JP 2000-290129 A JP 2001-39849 A JP 2004-67590 A Japanese Patent Application Laid-Open No. 08-73364 JP 2003-95852 A JP 2000-44481 A JP 2001-220347 A Soo J. Kim et.al., Biol., Pharm., Bull., 26 (9), 1348-1350, (2003) Yoko Ogiya et al. “Sapporo City Iken Annual Report” 29, 83-89, (2002)

  The present invention has been made under such circumstances, and an object of the present invention is to provide a technique for preventing serious inflammation and preventing runaway of the inflammatory system.

In view of such circumstances, the present inventors have made extensive research efforts to prevent the serious inflammation and prevent the runaway of the inflammatory system. 1) Soforaflavanone G The external preparation for skin containing 0.00001 to 0.1% by mass and 2) 0.01 to 1% by mass of soy isoflavone and / or glycoside thereof has such characteristics. The headline and invention were completed. That is, the present invention is as follows.
(1) Skin containing 0.00001-0.1% by mass of 1) sophoraflavanone G and 2) 0.01-1% by mass of soy isoflavone and / or glycoside thereof Topical agent.

ソフォラフラバノンＧ

Sophora Flabanon G

(2) The sophoraflavanone G is obtained by liquid-liquid extraction of an alcoholic extract of leguminous cucumbers (Sophora flavescens) with ethyl acetate and water, concentrating the ethyl acetate phase, and then separating by column chromatography using silica gel as a carrier. The external preparation for skin according to (1), which is derived from a product that has been purified.
(3) The soybean isoflavone is derived from a product obtained by extracting soybean with normal butyl alcohol, adding water thereto, liquid-liquid extracting, then removing the normal butyl alcohol layer and removing the solvent. The external preparation for skin according to (1) or (2).
(4) 1) Alcohol extract of leguminous cucumber (Sophora flavescens) is liquid-liquid extracted with ethyl acetate and water, and the ethyl acetate phase is concentrated, followed by fractional purification by column chromatography using silica gel as a carrier Solvent-removed component 0.0002 to 0.2 mass%, 2) Soybean extracted with normal butyl alcohol, water added thereto, liquid-liquid extraction, normal butyl alcohol layer taken and solvent removed The skin external preparation characterized by containing 1-0.1 mass%.
(5) The skin according to any one of (1) to (4), further comprising one or more selected from glycyrrhizic acid, alkyl glycyrrhetinate, and salts thereof. Topical agent.
(6) The content of one or more selected from the above-mentioned glycyrrhizic acid, alkyl glycyrrhetinate and salts thereof is 0.01 to 0.5% by mass, (5) The skin external preparation described in 1.
(7) The external preparation for skin according to (5) or (6), which is a quasi-drug that promotes anti-inflammatory action.
(8) In the indication, the indication that it is a quasi-drug that appealed to suppress the inflammation and its usage, take an appropriate amount, and include it in cut cotton etc. in the site with mild inflammation, Lightly rubbing it and applying it by pressing, indicating that it will be used by application, indicating that it reduces inflammation by applying, and stopping the use immediately if you feel tingling or burning The external preparation for skin according to (7), characterized in that the indication of the effect is constituted.
(9) A phospholipid microsphere comprising 1) sophoraflavanone G and 2) soybean isoflavone and / or glycoside thereof.
(10) The phospholipid microsphere according to claim 9, which is adjusted by a high-pressure emulsification apparatus.
(11) The phospholipid microsphere according to (9) or (10), wherein the outer wall contains hydrogenated soybean phospholipid.
(12) In the external preparation for skin described in (1) to (8), the content of sophoraflavanone G, soybean isoflavone and / or glycoside thereof is any one of (9) to (11) The external preparation for skin according to any one of (1) to (8), wherein the external preparation is a phospholipid microsphere.

  According to the present invention, it is possible to provide a technique for preventing serious inflammation and preventing runaway of the inflammatory system.

(1) Soforaflavanone G which is an essential component of the external preparation for skin of the present invention
The skin external preparation of the present invention is characterized by containing, as an essential component, Sophoraflavanone G and / or a salt thereof in an amount of 0.00001 to 0.001% by mass, more preferably 0.00002 to 0.0005% by mass. . Soforaflavanone G contains 10-50 mg in 1 kg of dried cucumber plant, and when water or the like is used as an extraction solvent, this component is difficult to elute and is usually extracted with ethanol or the like. When removed, an amorphous material containing 0.01 to 0.05% by mass of sophoraflavanone G is obtained. By liquid-liquid extraction of this extract with ethyl acetate and water and concentrating the ethyl acetate phase, an amorphous containing 0.1 to 1% by mass of sophoraflavanone G is obtained. Further, a fraction containing 30-50% by mass of sophoraflavanone G can be obtained by fractionating and purifying the product by silica gel column chromatography (elution solvent chloroform, chloroform / methanol mixed solution). When extracting with ethanol from kujin, a rhizome can be particularly preferably exemplified as a plant part to be used. Extraction is done by chopping up the plant body, etc., adding 1 to 10 times the solvent to this, adding it to room temperature for several days, and if it is near the boiling point for several hours, soaking with appropriate stirring do it. Thereafter, the mixture is cooled to room temperature, and then an insoluble matter is removed by filtration, if desired, followed by concentration under reduced pressure to obtain amorphous. The fraction purification of this product is preferably carried out while checking the situation by thin layer chromatography or the like, and when this is a mixed solvent of chloroform (95 parts by volume) and methanol (5 parts by volume), It appears as a spot at about Rf 0.1. In the present invention, it is preferable that sophoraflavanone G is contained in the above-mentioned quantitative ratio in the form of a fraction / purified product of the leguminous cucumber extract. When it is contained, it is particularly preferable that it is contained in phospholipid microspheres together with eugenol described later. In the external preparation for skin of the present invention, sophoraflavanone G works together with eugenol described later to calm down a runaway inflammatory factor, cut off a vicious cycle of inflammation, and exert an action of preventing damage accumulation in the living body. Such an action is not preferable because the content of sophoraflavanone G in the external preparation for skin is less than 0.0001% by mass in the form of phospholipid spherules. Even if the content exceeds 0.01 mass%, the effect may reach its peak, which is not preferable. Below, the manufacture example of an extraction refinement | purification suitable for containing Sophoraflavanone G of such quantity ratio is shown.

<Production Example 1>
1 kg of dried leguminous rhizomes was chopped, 10 l of ethanol was added thereto, heated under reflux for 3 hours with stirring, cooled to room temperature, and concentrated under reduced pressure. To this was added 2 l of water and 2 l of ethyl acetate to solubilize and liquid-liquid extraction was performed. The ethyl acetate phase was taken and concentrated to give 105 g of amorphous. The amount of Sophoraflavanone G contained in this product was determined to be 0.9% by mass. (ODS column 4.6 mm × 150 mm, column temperature 40 ° C., elution solvent 30% acetonitrile aqueous solution, flow rate 1 ml / min, detection ultraviolet part 220 nm, quantitative by absolute calibration curve using standard substance) silica gel column chromatography (chloroform, chloroform When the methanol mixture was purified with an elution solvent), 1.2 g of amorphous containing 38% by mass of sophoraflavanone G was obtained. This was dissolved in 200 ml of 60% 1,3-butanediol aqueous solution to prepare Diluent 1.

(2) Soy isoflavone and / or glycoside thereof, which is an essential component of the skin external preparation of the present invention, is 0.01 to 1% by mass of soy isoflavone and / or glycoside thereof. Preferably, 0.02 to 0.5% by mass is contained. Here, soybean isoflavone means a general term for flavonoids present in soybean, and its main component takes the form of a glycoside of isoflavonoid. Examples of isoflavonoids present in soybean include daidzein, genistein, and glycitein. Examples of glycosides include soybean in, genistin, and glycitin. It is already known that these components are contained in an amount of 5 to 10 mg per 1 g of dried soybean. Most of these are contained in the form of glycosides. (For example, refer nonpatent literature 2) As a method of obtaining this soybean isoflavone and / or its glycoside from soybean, for example, what grind | pulverized soybean finely is adjusted to acidity by adding acetic acid etc. as needed. Extract with alcohol such as ethanol, isopropyl alcohol or butyl alcohol containing water, remove the solvent if necessary, perform liquid-liquid extraction with normal butanol and water, take the butanol layer and concentrate An extract containing 30 to 60% by mass of soybean isoflavones (12 to 36% by mass in terms of aglycone) is obtained. As for soybean isoflavones, daidzein, genistein, glycitein and the like are sold in reagent grade by Fujicco Co., Ltd., and can be quantified by high performance liquid chromatography using those reagent grades as standard products. As the conditions for high performance liquid chromatography, a 4.4 × 150 mm ODS column (TSK gel-80TM) was used with 0.2% acetic acid and 0.1% sodium acetate and 25% acetonitrile aqueous solution as the mobile phase, and the column temperature was 40 ° C. It can be preferably exemplified that the absorption at the ultraviolet region of 256 nm is analyzed as a detection condition at a flow rate of 1 ml / min. In the external preparation for skin of the present invention, such soybean isoflavone and / or its glycoside can be contained alone or in combination of two or more. Such a component works together with the sophoraflavanone G to express an action for preventing inflammation.

<Production Example 2>
After crushing 500 g of dried soybeans with a coffee mill, 1 ml of glacial acetic acid and 2 l of 50% ethanol aqueous solution were added thereto, heated to reflux for 2 hours, cooled to room temperature, insolubles were removed by filtration, and concentrated under reduced pressure. 500 ml of water and 500 ml of normal butyl alcohol were added and dissolved, followed by liquid-liquid extraction, butanol layer was taken and concentrated under reduced pressure to obtain 3.8 g of amorphous. The amount of soybean isoflavone and its glycoside in this product was 1.8 g in terms of aglycone. (47.4%)

  Such soybean isoflavones and / or glycosides thereof are preferably encapsulated in phospholipid globules together with the sophoraflavanone G, and then contained in an external preparation for skin.

  As a method of encapsulating the sophoraflavanone G or oyster isoflavone and / or glycoside thereof in a phospholipid microsphere, a generally known method may be used. For example, the phospholipid is dissolved in a polyhydric alcohol in advance. Then, this is gradually added to the inner aqueous phase containing water to prepare an emulsion, and a system of small spheres may be uniformly prepared using a high-pressure emulsifier such as an extruder or a microfluidizer. As a component which comprises the wall of this phospholipid microsphere, 80-95 mass% of the phospholipid which comprises this is adjusted, More preferably, 85-90 mass% is adjusted so that it may become hydrogenated phospholipid. Furthermore, it is preferable to contain 5 to 20% by mass, more preferably 10 to 15% by mass of glycosphingolipid with respect to the total amount of phospholipid.

(3) External preparation for skin of the present invention The external preparation for skin of the present invention contains the above-mentioned essential components, prevents inflammation accompanied by runaway of inflammatory factors induced by ultraviolet irradiation, and injuries to living bodies caused by inflammation caused by ultraviolet irradiation Has the effect of making the lighter. In the external preparation for skin of the present invention, it is preferable to contain an active ingredient used for UV damage in addition to the above essential ingredients. Examples of the active ingredient include indomethacin, ketoprofen, glycyrrhizic acid and Preferred examples include / and salts thereof, anti-inflammatory agents such as glycyrrhetinic acid and / or esters thereof. As the anti-inflammatory agent, glycyrrhizic acid and / or a salt thereof, glycyrrhetinic acid and / or an alkyl ester thereof is more preferable. Glycyrrhizic acid and / or its salt is preferably dipotassium glycyrrhizinate, and alkyl glycyrrhetinate and / or its salt is preferably stearyl glycyrrhetinate. Such ingredients are known as active ingredients of quasi-drugs, and if these ingredients can be stably blended, quasi-drugs that have demonstrated anti-inflammatory effects by containing these components in predetermined amounts. It can be. This is because high-dose ultraviolet irradiation is stable and safe. The preferable content of such components is 0.01 to 0.5% by mass and 0.03 to 0.1% by mass with respect to the total amount of the external preparation for skin. This is because if the amount is too small, the effect may not be achieved, and if the amount is too large, the effect may reach a peak.

  In the external preparation for skin of the present invention, in addition to the above-mentioned components, optional components that are usually used in cosmetics and external preparations for skin can be contained. Such optional ingredients include, for example, macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil Oils such as hardened oil, mole, hardened castor oil, beeswax, candelilla wax, carnauba wax, ibotarou, lanolin, reduced lanolin, hard lanolin, jojoba wax, waxes, liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, petrolatum , Hydrocarbons such as microcrystalline wax, higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, undecylenic acid, cetyl alcohol, stearyl alcohol, isostearyl Alcohol, behenyl alcohol, octyldodecanol, higher alcohol such as myristyl alcohol, cetostearyl alcohol, cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, di-2-ethylhexyl sebacate, cetyl lactate, malic acid Diisostearyl, di-2-ethylhexanoic acid ethylene glycol, dicaprate neopentyl glycol, di-2-heptylundecanoic acid glycerin, tri-2-ethylhexanoic acid glycerin, tri-2-ethylhexanoic acid trimethylolpropane, tri Synthetic ester oils such as trimethylolpropane isostearate and pentane erythritol tetra-2-ethylhexanoate, dimethylpolysiloxane, methylphenylpoly Loxane, linear polysiloxane such as diphenylpolysiloxane, cyclic polysiloxane such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexanesiloxane, amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, Oil agents such as silicone oil such as modified polysiloxane such as fluorine-modified polysiloxane, anionic surfactants such as fatty acid soap (sodium laurate, sodium palmitate, etc.), potassium lauryl sulfate, triethanolamine ether of alkyl sulfate, chloride Cationic surfactants such as stearyltrimethylammonium, benzalkonium chloride, laurylamine oxide, imidazoline-based amphoteric surfactants (2-cocoyl-2-imida Zolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine surfactants (alkyl betaine, amide betaine, sulfobetaine, etc.), amphoteric surfactants such as acylmethyltaurine, sorbitan fatty acid esters (sorbitan) Monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (eg, glyceryl monostearate), propylene glycol fatty acid esters (eg, propylene glycol monostearate), hardened castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbite fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid ester Tells (POE-glycerol monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE2-octyldodecyl ether, etc.), POE alkylphenyl ethers (POE nonylphenyl) Ethers, etc.), Pluronic types, POE / POP alkyl ethers (POE / POP2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hardened castor oil derivatives (POE castor oil, POE hardened castor oil, etc.), Nonionic surfactants such as sucrose fatty acid ester and alkyl glucoside, polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene Polyols such as recall, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexylene glycol, 1,2-hexanediol, 1,2-octanediol, pyrrolidone carboxylic acid Moisturizing ingredients such as sodium, lactic acid, sodium lactate, guar gum, quince seed, carrageenan, galactan, gum arabic, pectin, mannan, starch, xanthan gum, curdlan, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylhydroxypropylcellulose, chondroitin sulfate , Dermatan sulfate, glycogen, heparan sulfate, hyaluronic acid, sodium hyaluronate, tragacanth gum, keratan sulfate, chondroitin, mucoitin sulfate, hyaluronan Droxyethyl guar gum, carboxymethyl guar gum, dextran, keratosulfuric acid, locust bean gum, succinoglucan, caronic acid, chitin, chitosan, carboxymethylchitin, agar, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium polyacrylate, Thickeners such as polyethylene glycol and bentonite, surface may be treated, powder such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, silicic anhydride (silica), aluminum oxide, barium sulfate The surface may be treated, bengara, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine, bitumen, titanium oxide, zinc oxide inorganic pigments, the surface may be treated, mica titanium, Fish phosphorus foil, bismuth oxychloride Pearl agents, which may be raked Red 202, Red 228, Red 226, Yellow 4, Blue 404, Yellow 5, Red 505, Red 230, Red 223, Orange 201 No., Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, Red No. 204, and the like, polyethylene powder, polymethyl methacrylate, nylon powder, organopolysiloxane elastomer Organic powders such as paraaminobenzoic acid UV absorbers, anthranilic acid UV absorbers, salicylic acid UV absorbers, cinnamic acid UV absorbers, benzophenone UV absorbers, sugar UV absorbers, 2- ( 2′-hydroxy-5′-t-octylphenyl) benzotriazole, 4-methoxy-4′-t-butyldibenzoylmethane, etc. External line absorbers, lower alcohols such as ethanol and isopropanol, vitamin A or its derivatives, vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or its derivatives, vitamin B12, vitamin B15 or its derivatives, etc. Vitamin E such as vitamin B, α-tocopherol, β-tocopherol, γ-tocopherol, vitamin E acetate, vitamin D, vitamin H, pantothenic acid, panthetin, pyrroloquinoline quinone, and the like can be preferably exemplified . Among these, in the external preparation for skin of the present invention, the content of the nonionic surfactant added with polyoxyethylene is preferably at most 1% by mass in order to enhance the stability of the phospholipid microspheres. It is preferable to keep it at 0.7% by mass. The skin external preparation of this invention can be manufactured by processing these according to a conventional method.

  Hereinafter, the present invention will be described in more detail with reference to examples, but it goes without saying that the present invention is not limited to such examples.

  In accordance with the formulation shown below, emulsion 1 (cosmetics; quasi-drugs that appealed anti-inflammatory) as an external preparation for skin of the present invention was prepared. Prior to the preparation of the emulsion, phospholipid spherules to be blended therein were prepared in advance. That is, the components of a) and b) were heated to 70 ° C., and b) was gradually added to b) with stirring to prepare a crude emulsion, which was then used as a high-pressure emulsifier “Microfluidizer” (MFI). Manufactured) to prepare small spheres, stirred and cooled to obtain intermediate work-in-process products for producing emulsions. Next, the components c) and d) are heated to 80 ° C., respectively, and d) is gradually added to C) with stirring. The mixture is cooled with stirring, and at 40 ° C., the phospholipid globule of e) is added, The emulsion was cooled to room temperature.

(Phospholipid globules 1)
B)
Hydrogenated soybean phospholipid 2.1% by mass
Soybean phospholipid 0.3% by mass
Glycosphingolipid 0.3% by mass
Glycerin 21.4% by mass
1,3-butanediol 14.2% by mass
Diluent 1 (Production Example 1) 0.3% by mass
(Soforaflavanone G0.000684%)
Eugenol 0.3% by mass
Royal jelly 1,3-butanediol extract 3% by mass
B)
Soy protein 0.3% by mass
Extract of Production Example 2 3% by mass
(Aglycon conversion soybean isoflavone amount 1.43%)
54.8% by weight of water

C)
Squalane 8% by mass
N-lauroyl-L-glutamate di (phytosteryl / octyldodecyl)
“El Dew PS-203” (manufactured by Ajinomoto Co., Inc.) 5% by mass
Macadamia nut oil 2% by mass
Stearyl alcohol 2.5% by mass
Stearic acid 1% by mass
Stearyl glycyrrhetinate 10% aqueous solution 0.5% by mass
Hydrogenated phospholipid 0.2% by mass
D)
Decaglycerin tristearate 2% by mass
Decaglycerin monooleate 2% by mass
Methylparaben 0.3% by mass
Phenoxyethanol 0.3% by mass
Glycerin 53.7% by mass
Diglycerin 3% by mass
Quince extract 2% by mass
POE (20) behenyl ether 0.5% by mass
1,3-butanediol 8% by mass
5.5% by weight of water
E)
Phospholipid spherule 1 3.5% by mass
(Sophoraflavanone G0.0000228% by mass,
Soybean isoflavone and its glycoside containing 0.05% by mass)

<Test Example 1>
The prevention effect of inflammation of the emulsion 1 of Example 1 was confirmed. That is, five 2 cm × 3 cm parts are provided on the back of five panelists, one part is coated with 0.05 ml of latex 1 and wiped off after 30 minutes, and one part is provided with the diluted solution 1 of latex 1 A treatment with a 50% glycerin aqueous solution (Comparative Example 1) was treated in the same manner, and one site was replaced with a 50% glycerin aqueous solution (Comparative Example 2). One site was not treated with a contributor, but only irradiated, and the remaining part of the site was treated as an untreated subject with neither sample administration nor ultraviolet irradiation. Ultraviolet irradiation of 1.5 times the minimum erythema dose (MED) measured in advance 1 hour after wiping was performed, and 12 hours later, the color difference (ΔE) relative to the untreated control site was measured. The results are shown in Table 1. From this, it can be seen that the skin external preparation of the present invention has an excellent inflammation preventing effect. It can also be seen that this effect is due to the combination of Sophoraflavanone G and soybean isoflavone and / or its glycoside.

  In the same manner as in Example 1, an emulsion 2 was prepared according to the formulation shown below. Evaluation was performed in the same manner as in Test Example 1. The results are shown in Table 2. From this, it can be seen that in the external preparation for skin of the present invention, it is preferable to use hydrogenated phospholipid as the phospholipid constituting the wall of the phospholipid microsphere.

(Phospholipid globules 2)
B)
Soybean phospholipid 2.4% by mass
Glycosphingolipid 0.3% by mass
Glycerin 21.4% by mass
1,3-butanediol 14.2% by mass
Diluent 1 (Production Example 1) 0.3% by mass
(Soforaflavanone G0.000684%)
Eugenol 0.3% by mass
Royal jelly 1,3-butanediol extract 3% by mass
B)
Soy protein 0.3% by mass
Extract of Production Example 2 3% by mass
(Aglycon conversion soybean isoflavone amount 1.43%)
54.8% by weight of water

C)
Squalane 8% by mass
N-lauroyl-L-glutamate di (phytosteryl / octyldodecyl)
“El Dew PS-203” (manufactured by Ajinomoto Co., Inc.) 5% by mass
Macadamia nut oil 2% by mass
Stearyl alcohol 2.5% by mass
Stearic acid 1% by mass
Stearyl glycyrrhetinate 10% aqueous solution 0.5% by mass
Hydrogenated phospholipid 0.2% by mass
D)
Decaglycerin tristearate 2% by mass
Decaglycerin monooleate 2% by mass
Methylparaben 0.3% by mass
Phenoxyethanol 0.3% by mass
Glycerin 53.7% by mass
Diglycerin 3% by mass
Quince extract 2% by mass
POE (20) behenyl ether 0.5% by mass
1,3-butanediol 8% by mass
5.5% by weight of water
E)
Phospholipid spherule 2 3.5% by mass
(Sophoraflavanone G0.0000228% by mass,
Soybean isoflavone and its glycoside containing 0.05% by mass)

  In the same manner as in Example 1, an emulsion 2 was prepared according to the formulation shown below. Evaluation was performed in the same manner as in Test Example 1. The results are shown in Table 2. From this, it can be seen that the skin external preparation of the present invention can contain soy isoflavone in a pure form.

(Phospholipid globule 3)
B)
Hydrogenated soybean phospholipid 2.1% by mass
Soybean phospholipid 0.3% by mass
Glycosphingolipid 0.3% by mass
Glycerin 21.4% by mass
1,3-butanediol 14.2% by mass
Diluent 1 (Production Example 1) 0.3% by mass
(Soforaflavanone G0.000684%)
Eugenol 0.3% by mass
Royal jelly 1,3-butanediol extract 3% by mass
B)
Soy protein 0.3% by mass
Genistine 3% by mass
54.8% by weight of water

C)
Squalane 8% by mass
N-lauroyl-L-glutamate di (phytosteryl / octyldodecyl)
“El Dew PS-203” (manufactured by Ajinomoto Co., Inc.) 5% by mass
Macadamia nut oil 2% by mass
Stearyl alcohol 2.5% by mass
Stearic acid 1% by mass
Stearyl glycyrrhetinate 10% aqueous solution 0.5% by mass
Hydrogenated phospholipid 0.2% by mass
D)
Decaglycerin tristearate 2% by mass
Decaglycerin monooleate 2% by mass
Methylparaben 0.3% by mass
Phenoxyethanol 0.3% by mass
Glycerin 53.7% by mass
Diglycerin 3% by mass
Quince extract 2% by mass
POE (20) behenyl ether 0.5% by mass
1,3-butanediol 8% by mass
5.5% by weight of water
E)
Phospholipid spherule 3 3.5% by mass
(Sophora Flavanone G 0.0000228% by mass contained,
Genistine 0.105 mass%)

  The present invention can be applied to a skin external preparation for preventing inflammation.

Claims (12)

1) Sophoraflavanone G contains 0.00001 to 0.1% by mass, 2) Soy isoflavone and / or glycoside thereof is contained in an amount of 0.01 to 1% by mass.

Sophora Flabanon G The sophoraflavanone G was liquid-liquid extracted with ethyl acetate and water from an alcohol extract of leguminous cucumber (Sophora flavescens), and the ethyl acetate phase was concentrated and purified by column chromatography using silica gel as a carrier. The external preparation for skin according to claim 1, which is derived from a product. The soy isoflavone is derived from a product obtained by extracting soybean with normal butyl alcohol, adding water thereto, liquid-liquid extraction, then removing the normal butyl alcohol layer and removing the solvent. The external preparation for skin according to claim 1 or 2. 1) Alcohol extract of leguminous cucumber (Sophora flavescens) was liquid-liquid extracted with ethyl acetate and water, the ethyl acetate phase was concentrated, fractionated and purified by column chromatography using silica gel as a carrier, and the solvent was removed. Ingredient 0.0002 to 0.2% by mass 2) Soybean extracted with normal butyl alcohol, water added thereto, liquid-liquid extraction, normal butyl alcohol layer taken and solvent removed 1-0 Skin external preparation characterized by containing 1 mass%. The skin external preparation according to any one of claims 1 to 4, further comprising one or more selected from glycyrrhizic acid, alkyl glycyrrhetinate and salts thereof. The content of one or more selected from the glycyrrhizic acid, alkyl glycyrrhetinate and salts thereof is 0.01 to 0.5% by mass, according to claim 5. Skin external preparation. The external preparation for skin according to claim 5 or 6, which is a quasi-drug that promotes anti-inflammatory action. In the labeling, the indication that it is a quasi-drug that appealed to suppress the inflammation, and in its usage, take an appropriate amount, and include it in a cut cotton etc. in a mildly inflamed area, and lightly An indication that it is applied and used by rubbing and pressing operation, an indication that the application reduces the inflammation, and an indication that the use is stopped immediately if a feeling of irritation or burning is felt by the above operation The external preparation for skin according to claim 7, wherein: 1. A phospholipid microsphere comprising 1) sophoraflavanone G and 2) soybean isoflavone and / or its glycoside. The phospholipid microsphere according to claim 9, which is prepared by a high-pressure emulsification apparatus. The phospholipid microsphere according to claim 9 or 10, wherein the outer wall contains hydrogenated soybean phospholipid. The skin external preparation according to any one of claims 1 to 8, wherein the sophoraflavanone G and soybean isoflavone and / or glycoside thereof are contained in the phospholipid microsphere according to any one of claims 9 to 11. The external preparation for skin according to any one of claims 1 to 8, wherein the preparation is external.